Viatris Stock Hammered After Earnings, Asset Sale - Investor's Business Daily

Viatris says the deal will give it the financial flexibility it needs for early-stage tests.

Viatris stock tumbled Monday after reporting mixed fourth-quarter earnings and a $3.34 billion plan to sell its biosimilars portfolio to Biocon Biologics. XThe Biocon deal includes products expected… [+1987 chars]

full article...